This study is for adults with stage I-III triple-negative breast cancer (TNBC) who didn't have a complete response after initial therapy. Triple-negative breast cancer (TNBC) is a type of breast cancer that doesn't have three common things found in most breast cancers, making it harder to treat. The study checks how well a new treatment, Dato-DXd, works alone or with a drug named durvalumab, against standard treatments known as ICT (investigator's choice therapy). ICT often includes drugs like capecitabine and pembrolizumab. The main aim is to see if Dato-DXd can help better than ICT.

• The study requires participants to be 18 years or older and have some cancer left after surgery.
• Eligible participants must not have had any previous breast cancer that came back or spread to other parts of the body.
• Participants should not have any other uncontrolled health issues or severe allergies to the study drugs.

People who join might need to provide a tumor sample and take part in scans and tests. The study is international, meaning people from different countries can join. There are no emojis in this study summary.